Tesaro Inc (TSRO)

118.86
5.00 4.39
NASDAQ : Health Care
Prev Close 113.86
Open 113.15
Day Low/High 113.12 / 119.46
52 Wk Low/High 29.51 / 94.01
Volume 1.39M
Avg Volume 1.28M
Exchange NASDAQ
Shares Outstanding 54.18M
Market Cap 5.91B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Market Recon: Worryingly, the Indices Seem to Be Almost Resting at Lofty Levels

Market Recon: Worryingly, the Indices Seem to Be Almost Resting at Lofty Levels

A mishap in northern Asia would be an awful catalyst even to ponder. But a less apocalyptic one would be oil.

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.

TESARO Announces Submission Of Investigational New Drug Application For Anti-LAG Antibody TSR-033 To The U.S. FDA

Phase 1 trial of TSR-033 planned to begin in mid-2017

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Tesaro, Editas

Cempra, Tesaro and Editas Medicine were among the biotech stock movers in premarket trading on Tuesday.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

TESARO Announces U.S. FDA Approval Of ZEJULA™ (Niraparib) For Women With Recurrent Ovarian Cancer

- ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.